Subscribe
shutterstock_1174421515_eyesonmilan
eyesonmilan / Shutterstock.com
20 May 2019Americas

Gilead claims US government PrEP patents are invalid

Gilead’s CEO has told a US House of Representatives committee that three Centers for Disease Control (CDC) HIV prevention patents are invalid.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Gilead challenges US govt patents on HIV drug Truvada
22 August 2019   Gilead Sciences, the maker of HIV drug Truvada, has asked the US Patent and Trademark Office to review patents granted to the government covering preventative use of the drug.
Americas
US government sues Gilead for patent infringement over HIV drugs
7 November 2019   The US government is suing Gilead for patent infringement, claiming that the pharmaceutical company has been piggybacking on public research to earn billions from its HIV drugs.
Big Pharma
Gilead sues US govt for breach of contract over antiviral patents
29 April 2020   Gilead has escalated its dispute with the US federal government by filing a new lawsuit accusing it of improperly filing for patents covering HIV drug Truvada.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Americas
Gilead challenges US govt patents on HIV drug Truvada
22 August 2019   Gilead Sciences, the maker of HIV drug Truvada, has asked the US Patent and Trademark Office to review patents granted to the government covering preventative use of the drug.
Americas
US government sues Gilead for patent infringement over HIV drugs
7 November 2019   The US government is suing Gilead for patent infringement, claiming that the pharmaceutical company has been piggybacking on public research to earn billions from its HIV drugs.
Big Pharma
Gilead sues US govt for breach of contract over antiviral patents
29 April 2020   Gilead has escalated its dispute with the US federal government by filing a new lawsuit accusing it of improperly filing for patents covering HIV drug Truvada.

More on this story

Americas
Gilead challenges US govt patents on HIV drug Truvada
22 August 2019   Gilead Sciences, the maker of HIV drug Truvada, has asked the US Patent and Trademark Office to review patents granted to the government covering preventative use of the drug.
Americas
US government sues Gilead for patent infringement over HIV drugs
7 November 2019   The US government is suing Gilead for patent infringement, claiming that the pharmaceutical company has been piggybacking on public research to earn billions from its HIV drugs.
Big Pharma
Gilead sues US govt for breach of contract over antiviral patents
29 April 2020   Gilead has escalated its dispute with the US federal government by filing a new lawsuit accusing it of improperly filing for patents covering HIV drug Truvada.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York